A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.
An international commission made the case for focusing on body fat quantity and the illnesses people experience.
US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...
The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Obesity medications promise transformative care, but financial and systemic barriers limit access for those most in need.
New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new ...
A coalition of obesity-related patient advocacy groups is calling on the incoming Trump administration to finalize a proposal ...
The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, ...
The average monthly retail price of the new class of obesity medications is $1,200 without insurance, according to Amy McHugh, a spokesperson for Blue Cross Blue Shield. About 7.5 percent of obese ...
As weight loss medications like Ozempic and Wegovy become increasingly popular, questions arise about whether the nation is approaching pea ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback